Piramal Pharma Solutions

Mumbai, India Founded: 1988 • Age: 38 yrs Listed
Serves as a contract manufacturer of pharmaceutical products for industry partners.

About Piramal Pharma Solutions

Piramal Pharma Solutions is a publicly listed company based in Mumbai (India) founded in 1988. It serves as a contract manufacturer of pharmaceutical products for industry partners. It operates on a B2B model. The company has 5,480 employees. Piramal Pharma Solutions has completed 1 acquisition, including Hemmo Pharmaceuticals. Its website piramalpharmasolutions.com draws about 16 thousand monthly visits. Its Indian entity Piramal Pharma Limited reported revenue of β‚Ή9,161 Cr. Its focus areas include Healthcare, Pharmaceuticals, Manufacturing and Contract Production. Its competitors include Syngene, Piramal Group and Panacea Biotec; 1 of its 3 listed competitors has raised funding.

Company details

Piramal Pharma Solutions, founded in 1988 in Mumbai, India, focuses on providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and contract production. Serves as a contract manufacturer of pharmaceutical products for industry partners. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.

Key Metrics
  • Market Cap
    ₹31,906 Cr

    PPLPHARMA · NSE

  • Share Price
    ₹239.30

    -0.15% today

  • Revenue
    ₹8,869 Cr

    FY 2025-26 · -3.1% YoY

  • EBITDA
    ₹704 Cr

    Margin 7.9%

  • Net Profit
    −₹312 Cr

    FY 2025-26 · -451.5% YoY

  • ROE
    -3.8%

    ROCE 2.5%

  • Debt / Equity
    0.65

    Interest cover -267.9x

  • Employee Count
    5,480
  • Investments & Acquisitions

Apps and channels of Piramal Pharma Solutions

its YouTube channel Piramal Pharma Solutions has 9.09K subscribers and 30 videos.

Piramal Pharma Solutions
YouTube 9.09K subscribers 30 videos Science & Technology
Open channel

Videos from Piramal Pharma Solutions

The most watched videos on Piramal Pharma Solutions's YouTube channel, Piramal Pharma Solutions (9.09K subscribers). Click a video to play it here.

Piramal Pharma Solutions: Grangemouth, UK
462 views
Piramal Pharma Solutions Operational Excellence
457 views
Piramal Pharmas Associate Company Yapan Bio Pvt Ltd.
388 views
Piramal Pharma announces $85M Expansion Plan for Sterile Injectables Facility in Lexington, Kentucky
337 views

More on Piramal Pharma Solutions.

Board of directors of Piramal Pharma Limited (Piramal Pharma Solutions)

Piramal Pharma Limited is the primary company behind Piramal Pharma Solutions. The board of Piramal Pharma Limited currently have 10 directors; the longest-serving is Peter D Deyoung, appointed in 2020. 2 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Peter D Deyoung
DIN 07152550
Whole-time director04 Mar 20206 yrs 8 moPiramal Pharma Limited
Nandini Ajay Piramal
DIN 00286092
Whole-time director04 Mar 20206 yrs 8 moPiramal Pharma Limited
Jairaj Manohar Purandare
DIN 00159886
Director09 Feb 20215 yrs 9 moPiramal Pharma Limited
Vivek Valsaraj
DIN 06970246
Whole-time director09 Feb 20224 yrs 9 moPiramal Pharma Limited
Sridhar Gorthi
DIN 00035824
Director30 Mar 20224 yrs 7 moPiramal Pharma Limited
Peter Andrew Stevenson
DIN 09544706
Director30 Mar 20224 yrs 7 moPiramal Pharma Limited
Vibha Paul Rishi
DIN 05180796
Director30 Aug 20224 yrs 2 moPiramal Pharma Limited
Nathalie Ann Leitch
DIN 09557042
Director28 Jan 20251 yr 9 moPiramal Pharma Limited
Amit Jain
DIN 06917608
Director14 May 20251 yr 6 moPiramal Pharma Limited
Amit Soni
DIN 05111144
Director09 Feb 20269 moPiramal Pharma Limited

People of Piramal Pharma Solutions

51 people are tracked at Piramal Pharma Solutions (29 in leadership, 1 in board & advisors, 21 in team); the tracked headcount is 5,480.

NameRoleGroup
Michael Teague
Executive VP Global Operations at Piramal Critical Care Inc.Leadership
Christopher Leahy
Senior Vice President, FinanceLeadership
Satyajit Tillu
Senior General Manager & Site HeadLeadership
Susie Hodgson
Director Of Finance And ProcurementLeadership
Debashish Chakravorty
Executive Vice President, India FormulationsLeadership
Stuart Needleman
Chief Commercial Officer & Chief Patient Centricity OfficerLeadership
Sujatha Kumar
General Manager L & D Global PharnaLeadership
Yogita Karakkadavath
Chief Manager - Corporate IPLeadership
Deepika Maskara
Global Head - Total Rewards And Corporate HR HeadLeadership
Executive Director & CEOLeadership
Ravindra Pawar
Deputy Chief ManagerLeadership
Anil Jaiswal
Head Of Human ResourcesLeadership
John Nause
Director, International Compliance/chief Compliance OfficerLeadership
Anagha Deshpande
Vice President Finance & ITLeadership
Abhishek Fanse
Deputy Chief Manager - Human Resources And AdministrationLeadership
Ca Neelam Valani
Chief Manager FinanceLeadership
Puneet Rajput
Chief Human Resources OfficerLeadership
Swapnil Thakkar
Head Of Contract Manufacturing & ProcurementLeadership
Girish Guna
Head - Indirect TaxLeadership
Manish Punjabi
Head - Learning & Development And Campus Talent ManagementLeadership

31 more people are available in the full profile.

Premium access

Complete people profiles for Piramal Pharma Solutions

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Piramal Pharma Solutions

Piramal Pharma Solutions is a publicly listed company on the NSE with ticker symbol PPLPHARMA in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: PPLPHARMA
  • Listed entityPiramal Pharma Limited
  • Exchange sectorPharmaceuticals

Financials of Piramal Pharma Solutions

Exchange-reported figures of Piramal Pharma Limited, the listed company behind Piramal Pharma Solutions (NSE: PPLPHARMA).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹8,869 Cr
-3.1% YoY
EBITDA
₹704 Cr
-51.3% YoY
Profit After Tax
−₹312 Cr
-451.5% YoY
Net Worth
₹8,163 Cr
+0.5% YoY
Total Assets
₹14,088 Cr
+6.7% YoY
Total Debt
₹5,675 Cr
+16.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue8,8699,1518,1717,0826,5596,315
Revenue growth-3.1%+12.0%+15.4%+8.0%+3.9%-
EBITDA7041,4451,1336219351,428
EBITDA margin+7.9%+15.8%+13.9%+8.8%+14.3%+22.6%
Profit before tax(176)415179(120)485949
Net profit(312)88.8215.83(186)384818
Net profit margin-3.5%+1.0%+0.2%-2.6%+5.9%+13.0%
EPS (β‚Ή)(2.46)0.690.13(1.56)3.178.40
Balance sheet
Total assets14,08813,20612,82212,61210,9918,780
Net worth8,1638,1257,9116,7746,6975,605
Total debt5,6754,8564,7105,6374,1283,025
Cash & bank1,224501483308329406
Net working capital3,5413,5543,0592,7172,4031,751
Cash flow
Cash from operations1,6538921,005484766598
Cash from investing(820)(488)(416)(1,334)(1,737)(4,464)
Cash from financing(38.98)(441)(422)8187943,977
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,6172,2702,7522,1402,0441,9342,7542,204
Revenue growth (YoY)+28.1%+17.4%-0.1%-2.9%-8.8%-0.9%--
Other income53.6710959.6353.5080.3997.7158.2529.18
EBITDA349195285155159107561338
EBITDA margin+13.3%+8.6%+10.3%+7.2%+7.8%+5.5%+20.4%+15.3%
Depreciation233224218213203197243197
Interest87.6388.0882.9989.2482.4286.15104103
Profit before tax81.63(7.46)43.00(93.86)(46.18)(79.02)27366.80
Tax76.6061.9351.8342.3353.042.6811963.12
Net profit5.03(69.39)(8.83)(136)(99.22)(81.70)1543.68
EPS (β‚Ή)0.04(0.52)(0.07)(1.03)(0.75)(0.62)1.160.03
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue4,7825,2864,3903,4433,3402,939
Revenue growth-9.5%+20.4%+27.5%+3.1%+13.7%-
EBITDA5491,04061890.57460619
EBITDA margin+11.5%+19.7%+14.1%+2.6%+13.8%+21.1%
Profit before tax877911508124462687
Net profit76868938872.64378556
Net profit margin+16.1%+13.0%+8.8%+2.1%+11.3%+18.9%
EPS (β‚Ή)5.275.222.960.583.105.75
Balance sheet
Total assets9,0228,7447,9216,9366,3004,281
Net worth8,1417,4536,7125,2625,1234,101
Total debt7861,2431,1771,6491,164174
Cash & bank57417824264.16137152
Net working capital1,8422,1011,7971,3371,166463
Cash flow
Cash from operations1,32854935871.5224934.72
Cash from investing(318)(552)(635)(435)(1,165)(4,383)
Cash from financing(615)(61.74)4512908964,494
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,3451,1251,4891,1961,1279701,6901,248
Revenue growth (YoY)+19.4%+16.0%-11.9%-4.2%-12.2%-8.8%--
Other income13811518496.1520218139.5124.70
Total expenses1,1741,0081,2511,0561,0009261,2731,029
EBITDA17211723814012744.33417219
EBITDA margin+12.7%+10.4%+16.0%+11.7%+11.3%+4.6%+24.7%+17.6%
Depreciation67.5665.7370.1264.6961.2559.4461.1755.46
Interest17.2716.3619.5016.8420.3823.2330.5629.17
Profit before tax225149332155247143364159
Tax53.8636.0070.2226.0251.0829.4487.0940.61

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 21 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,6172,2702,7522,1402,0441,9342,7542,204
Revenue growth (YoY)+28.1%+17.4%-0.1%-2.9%-8.8%-0.9%--
Other income53.6710959.6353.5080.3997.7158.2529.18
EBITDA349195285155159107561338
EBITDA margin+13.3%+8.6%+10.3%+7.2%+7.8%+5.5%+20.4%+15.3%
Depreciation233224218213203197243197
Interest87.6388.0882.9989.2482.4286.15104103
Profit before tax81.63(7.46)43.00(93.86)(46.18)(79.02)27366.80
Tax76.6061.9351.8342.3353.042.6811963.12
Net profit5.03(69.39)(8.83)(136)(99.22)(81.70)1543.68
EPS (β‚Ή)0.04(0.52)(0.07)(1.03)(0.75)(0.62)1.160.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue8,8699,1518,1717,0826,5596,315
Revenue growth-3.1%+12.0%+15.4%+8.0%+3.9%-
Other income292208235279335230
Total expenses8,1657,7067,0386,4605,6254,887
Employee cost2,4162,3072,0301,8961,5891,468
EBITDA7041,4451,1336219351,428
EBITDA margin+7.9%+15.8%+13.9%+8.8%+14.3%+22.6%
Depreciation831816741677586545
Interest341422448344198163
Profit before tax(176)415179(120)485949
Tax15032416166.31109114
Net profit(312)88.8215.83(186)384818
Net profit margin-3.5%+1.0%+0.2%-2.6%+5.9%+13.0%
EPS (β‚Ή)(2.46)0.690.13(1.56)3.178.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital1,3271,3241,3231,1931,186995
Reserves & surplus6,8356,8016,5885,5805,5114,610
Shareholders' funds (net worth)8,1638,1257,9116,7746,6975,605
Minority interest0.000.000.000.000.000.00
Secured loans5,4704,5904,5365,4973,9812,601
Unsecured loans204266174140146424
Total debt5,6754,8564,7105,6374,1283,025
Total liabilities14,08813,20612,82212,61210,9918,780
Assets
Gross block14,82913,07712,09910,8429,5108,153
Net block8,6848,1337,9907,4696,8796,105
Capital work in progress1,1009771,1161,4191,172627
Investments437291385639267123
Inventories3,0642,3132,1761,6811,3891,232
Sundry debtors2,1582,3502,1341,7991,7851,575
Cash & bank balances1,224501483308329406
Loans & advances614614527620514436
Total current assets7,0605,7775,3204,4084,0173,649
Total current liabilities3,5192,2232,2611,6911,6141,898
Net working capital3,5413,5543,0592,7172,4031,751
Total assets14,08813,20612,82212,61210,9918,780
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash18221953.2385.18262152
Net cash from operating activities1,6538921,005484766598
Net cash from investing activities(820)(488)(416)(1,334)(1,737)(4,464)
Net cash from financing activities(38.98)(441)(422)8187943,977
Net change in cash794(36.87)166(31.95)(177)110
Closing cash1,224501483308329406
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-3.1%+12.0%+15.4%+8.0%+3.9%-
EBITDA growth-51.3%+27.5%+82.4%-33.5%-34.6%-
PBT growth-+131.3%+9998.0%--48.9%+9997.0%
Net income growth-451.5%+461.1%+108.5%-148.4%-53.0%-
Revenue CAGR (3Y)+7.8%+11.7%+9.0%---
EBITDA CAGR (3Y)+4.3%+15.6%-7.4%---
Profitability & leverage
Net income margin-3.7%+1.0%+0.2%-2.6%+5.7%+13.2%
Return on capital employed+2.5%+6.4%+5.4%+1.9%+6.9%+12.7%
Return on net worth-3.8%+1.1%+0.2%-2.8%+6.1%+14.9%
Debt / equity0.650.600.700.720.580.54
Long-term debt / equity0.480.370.410.460.420.43
Interest cover-267.9567.08114.15-621.1556.9018.51
Efficiency & per share
Fixed asset turnover0.640.730.710.700.740.77
Inventory turnover3.304.084.244.615.015.13
Debtors turnover3.944.084.153.953.904.01
EPS (β‚Ή)(2.46)0.690.13(1.56)3.178.40
Dividend per share (β‚Ή)0.000.140.110.000.560.00
Book value per share (β‚Ή)61.5061.3559.8056.7656.4756.35
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,3451,1251,4891,1961,1279701,6901,248
Revenue growth (YoY)+19.4%+16.0%-11.9%-4.2%-12.2%-8.8%--
Other income13811518496.1520218139.5124.70
Total expenses1,1741,0081,2511,0561,0009261,2731,029
EBITDA17211723814012744.33417219
EBITDA margin+12.7%+10.4%+16.0%+11.7%+11.3%+4.6%+24.7%+17.6%
Depreciation67.5665.7370.1264.6961.2559.4461.1755.46
Interest17.2716.3619.5016.8420.3823.2330.5629.17
Profit before tax225149332155247143364159
Tax53.8636.0070.2226.0251.0829.4487.0940.61
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue4,7825,2864,3903,4433,3402,939
Revenue growth-9.5%+20.4%+27.5%+3.1%+13.7%-
Other income663207202341225216
Total expenses4,2334,2453,7723,3532,8802,320
Employee cost745736614548448395
EBITDA5491,04061890.57460619
EBITDA margin+11.5%+19.7%+14.1%+2.6%+13.8%+21.1%
Depreciation256222205192165144
Interest79.9511510711657.294.71
Profit before tax877911508124462687
Tax17722011654.1994.79115
Net profit76868938872.64378556
Net profit margin+16.1%+13.0%+8.8%+2.1%+11.3%+18.9%
EPS (β‚Ή)5.275.222.960.583.105.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital1,3271,3241,3231,1931,186995
Reserves & surplus6,8146,1285,3894,0683,9373,106
Shareholders' funds (net worth)8,1417,4536,7125,2625,1234,101
Secured loans4211,0098961,3131,15490.20
Unsecured loans36523428133610.6984.06
Total debt7861,2431,1771,6491,164174
Total liabilities9,0228,7447,9216,9366,3004,281
Assets
Gross block4,5754,2493,7673,5653,2252,260
Net block3,0362,8942,6122,6022,4391,627
Capital work in progress221327533417405121
Investments3,5803,1051,7081,7471,6301,592
Inventories1,8731,2051,153819536421
Sundry debtors1,4061,6671,331910989840
Cash & bank balances57417824264.16137152
Loans & advances451486504456403355
Total current assets4,3053,5363,2302,2492,0651,768
Total current liabilities2,4621,4341,4339128991,305
Net working capital1,8422,1011,7971,3371,166463
Total assets9,0228,7447,9216,9366,3004,281
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash16422954.281281470.74
Net cash from operating activities1,32854935871.5224934.72
Net cash from investing activities(318)(552)(635)(435)(1,165)(4,383)
Net cash from financing activities(615)(61.74)4512908964,494
Net change in cash395(64.93)175(73.41)(19.03)146
Closing cash57417824264.16137152
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-9.5%+20.4%+27.5%+3.1%+13.7%-
EBITDA growth-47.2%+68.4%+582.3%-80.3%-25.7%-
PBT growth-3.8%+79.5%+310.4%-73.3%-32.7%+9997.0%
Net income growth+11.4%+77.6%+434.0%-80.8%-32.0%-
Revenue CAGR (3Y)+11.6%+16.5%+14.3%---
EBITDA CAGR (3Y)+82.4%+31.3%-0.1%---
Profitability & leverage
Net income margin+14.6%+13.1%+8.9%+2.0%+11.0%+19.5%
Return on capital employed+10.8%+12.3%+8.3%+3.6%+9.8%+16.2%
Return on net worth+9.0%+9.8%+6.5%+1.3%+8.0%+13.9%
Debt / equity0.130.170.240.270.150.04
Long-term debt / equity0.050.050.080.110.050.00
Interest cover27.1914.0025.95-114.1519.430.99
Efficiency & per share
Fixed asset turnover1.081.321.201.011.221.30
Inventory turnover3.114.484.455.096.996.98
Debtors turnover3.113.533.923.633.653.50
EPS (β‚Ή)5.275.222.960.583.105.75
Dividend per share (β‚Ή)0.000.140.110.000.560.00
Book value per share (β‚Ή)61.3456.2750.7444.0943.2041.23

Investments & Acquisitions by Piramal Pharma Solutions

Piramal Pharma Solutions has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Hemmo Pharmaceuticals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Synthetic peptides are manufactured for research, clinical, and commercial applications.
hemmopharma.comMumbai, India1979Mar 2021$105.63M
Premium access

Complete acquisition details for Piramal Pharma Solutions

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Piramal Pharma Solutions

2 dated milestones of Piramal Pharma Solutions across 33 years, from founding to its latest funding, stage changes and deals.

  1. Founded Piramal Pharma Solutions is founded.
  2. Acquisition Acquires Hemmo Pharmaceuticals.

Competitors of Piramal Pharma Solutions

Piramal Pharma Solutions has 3 listed competitors in our database, 1 of them funded. They include Syngene, Piramal Group and Panacea Biotec.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
syngeneintl.com1993Bengaluru, India$85.89M5,618
Provider of contract research and manufacturing services for both small molecules and biologics
piramal.com1984Mumbai, India204
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate
panaceabiotec.com1984Ambala, India2,095
Developer of biosimilars, vaccines and natural products
Premium access

Detailed competitors of Piramal Pharma Solutions

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Piramal Pharma Solutions

The website of Piramal Pharma Solutions (piramalpharmasolutions.com) receives about 15.7K visits a month.

  • Monthly visits
    15.7K

    ▲ 26.8% vs previous month

Similar websites

Websites whose visitors overlap most with Piramal Pharma Solutions. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
piramal.com
100%
47K#586,886View details
outsourcing-pharma.com
78%
View details
heidelberg-pharma.com
77%
3.9K#1,811,054View details
healthbiotech.in
76%
#12,544,949View details
gmp-compliance.org
70%
#293,120View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 9 similar websites and full traffic analytics for Piramal Pharma Solutions

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 9 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Contract & Outsourced Manufacturing

3 companies that operate in the same segment as Piramal Pharma Solutions (Contract & Outsourced Manufacturing) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Industrial components, mould bases, and storage solutions are manufactured globally.
1986Coimbatore, Tamil Nadu, IndiaUSD 28 MUSD 853.09 M43
Single- and three-phase transformers are manufactured in Mumbai.
1993Mumbai, Maharashtra, IndiaUSD 114.37 M618
Apparel and clothing are manufactured and exported on contract.
1979Bengaluru, Karnataka, IndiaUSD 400 M40,280
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Piramal Pharma Solutions

Piramal Pharma: Board Committee Approves Plan To Buy Remaining 26% Stake In Yapan Bio.
Exchange Update β€’ 4 days ago
Piramal Pharma: Expects EBITDA Margins To Increase In H2 Of The Year
Exchange Update β€’ 25 days ago
PPLPHARMA: Q2 REVENUE 26.2B RUPEES VS 20.4B (YOY)
Exchange Update β€’ 26 days ago
PPLPHARMA: Q2 CONS NET PROFIT 56M RUPEES VS LOSS 992M (YOY); EST LOSS 701M
Exchange Update β€’ 26 days ago
PPLPHARMA: Q2 EBITDA 3.66B RUPEES VS 1.58B (YOY); Q2 EBITDA MARGIN 14% VS 7.73% (YOY)
Exchange Update β€’ 26 days ago
Premium access

Complete news archive for Piramal Pharma Solutions

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Piramal Pharma Solutions

Piramal Pharma Solutions was founded in 1988.

Piramal Pharma Solutions is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Piramal Pharma Solutions has 5,480 employees.

The primary company behind Piramal Pharma Solutions, Piramal Pharma Limited, reported revenue of β‚Ή9,161 Cr for FY 2026, down 3% year on year.

Piramal Pharma Solutions, founded in 1988 in Mumbai, India, focuses on providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and contract production. Serves as a contract manufacturer of pharmaceutical products for industry partners. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.

Piramal Pharma Solutions's top competitors include Syngene, Panacea Biotec and Piramal Group.

Yes, Piramal Pharma Solutions is publicly traded on NSE under the ticker symbol PPLPHARMA.

Piramal Pharma Solutions has made 1 acquisition, including Hemmo Pharmaceuticals.

Piramal Pharma Solutions operates through Piramal Pharma Limited.

The legal entities of Piramal Pharma Solutions currently have 11 directors, including Peter D Deyoung, Jairaj Manohar Purandare, Sridhar Gorthi and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available